Ventyx Biosciences, Inc. VTYX 深 滬
已收盤 01-30 16:00:00 美东时间
13.95
0.000
0.00%
華盛通- 最 高13.97
- 今 開13.96
- 成交量 101.47万股
- 最 低 13.93
- 昨 收 13.95
- 總市值 10.01亿
- 52周最高 25.00
- 市盈率 靜 --
- 換手率 1.41%
- 52周最低 0.783
- 委 比 51.89%
- 總股本 7175.01万
- 歷史最高 47.2508
- 量 比 0.54
- 振 幅 0.29%
- 歷史最低 0.783
- 每 手 1
- 風險率 3.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Oppenheimer Downgrades Ventyx Biosciences to Perform
Oppenheimer analyst Jeff Jones downgrades Ventyx Biosciences (NASDAQ:VTYX) from Outperform to Perform.
01-09 02:05
Alphabet To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-08 21:13
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
美股牛股 | 脑机接口概念持续强势！脑再生科技大涨超60%；Revolution涨超28.6%
脑机接口概念持续强势！脑再生科技大涨超60%，近四日涨幅超150%；“收购传闻”引股价过山车，Revolution隔夜涨超28.6%，盘后跌超6%>>
01-08 15:53
Lilly To Acquire Ventyx Biosciences For $14.00/Share In All-Cash Deal Valued At ~$1.2B
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammationAcquisition builds on Lilly's established capabilities in inflammatory-mediated
01-08 05:19
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in infla...
01-08 05:17
Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition
Eli Lilly shares are trading higher Wednesday following a report suggesting the company is nearing a deal for Ventyx Biosciences.
01-08 01:52
Market-Moving News for January 7th
GLUE: 42% | Monte Rosa Therapeutics shares are trading higher after the company announced it will present interim clinical results from the ongoing Phase 1 study of NEK7-directed MGD MRT-8102. VTYX: 74% |
01-07 20:17
美股牛股 | AI引爆涨价潮！SanDisk飙升超27%；Ventyx 涨超28%
AI引爆涨价潮！Sandisk飙升超27%；有望获礼来超10亿美元收购，Ventyx 涨超28%>>
01-07 15:44
